Phosphoproteomics unveils the mode of action of clinical ATR inhibitors and explains their synergy with Gemcitabine in ...

Teams of researchers are investigating empagliflozin and dapagliflozin in patients with autosomal dominant polycystic kidney disease (AD PKD).

Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...

CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone receptor-positive and HER2-negative. Currently, there are three CDK4/6 inhibitors approved ...

The application of PDE4 inhibitors appears to be a promising option to facilitate with minimal side effects the spontaneous passage of (distal) ureteral stones and relieve pain associated with ...

The new year is upon us, but before the calendar officially switches to 2025, there are still some great streaming deals to take advantage of. Specifically, over on Amazon. As part of its end-of ...

Meanwhile, other new therapies outside the JAK inhibitor class are also making waves in the AD market, notably Sanofi’s injectable antibody Dupixent (dupilumab) and Pfizer’s topical PDE-4 ...

Emraclidine (CVL-231) is under development for the treatment of schizophrenia experiencing an acute exacerbation of psychosis, dementia associated with Alzheimer's disease (AD) and Alzheimer ...

Given the lack of any effective alternatives, the use of cholinesterase inhibitors for the symptomatic treatment of mild-to-moderate Alzheimer's disease has become accepted practice, although the ...

Chemical Research Laboratories, Japan Tobacco, Inc., 1-1, Murasaki-cho, Takatsuki, Osaka 569-1125, Japan ...